The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients
NCT04966884
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Dermatomyositis, Adult Type
Interventions
DRUG:
JAK Inhibitor
Sponsor
First Affiliated Hospital Xi'an Jiaotong University